ABSTRACT
Improvement of elderly cancer patients' treatment is an acute issue in oncology. The results of stage III rectal and colon cancer complex treatment are far from being satisfactory in this category of patients. In this connection the search for new adjuvant drugs supplementing radio and chemotherapy is urgent. The article describes pioneer experience in complex radical treatment of elderly cancer patients with immunomodulator Vilon included into the scheme of treatment. The obtained preliminary results of investigation suggest recommendation of Vilon application to increase 2-year survival of patients, prevention of post-operative complications, remote complications, recurrences and tumor dissemination, as well as the improvement of the quality of life after employment of aggressive methods of treatment.
Subject(s)
Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/mortality , Dipeptides/therapeutic use , Immunologic Factors/therapeutic use , Adult , Aged , Colorectal Neoplasms/surgery , Combined Modality Therapy , Female , Humans , Middle Aged , Treatment OutcomeSubject(s)
Lung Neoplasms/surgery , Lymph Node Excision , Pneumonectomy/methods , Adult , Aged , Female , Humans , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Staging , PrognosisABSTRACT
Radical surgery adjuvant to pre- or postoperative teleradiotherapy and intravenous injection of radioactive colloid gold did not aggravate the course of the postoperative period in pulmonary carcinoma patients, nor did it increase the total number of postoperative complications and the postoperative mortality. Side effects of treatment presenting as radiation responses were transitory and cured conservatively. Three-component treatment for pulmonary carcinoma, including preoperative irradiation in doses 20, 30 Gy, radical surgery, and intravenous 198Au after surgery is indicated to patients with Stage III pulmonary adenocarcinoma and epidermoid cancer, whose 5-year survival rate elevated by 36 and 30 percent, respectively, as against surgical treatment, and to those with stages II and III metastatic adenocarcinoma and epidermoid cancer of the lungs, whose 5-year survival rate increased by 39 and 32 percent, respectively, as against those treated surgically.
